title: Design considerations for AIDS trials.
authors.affiliation: National Cancer Institute, Bethesda, MD 20892.
authors.forename: D P
authors.initials: DP
authors.lastname: Byar
authors.forename: D A
authors.initials: DA
authors.lastname: Schoenfeld
authors.forename: S B
authors.initials: SB
authors.lastname: Green
authors.forename: D A
authors.initials: DA
authors.lastname: Amato
authors.forename: R
authors.initials: R
authors.lastname: Davis
authors.forename: V
authors.initials: V
authors.lastname: De Gruttola
authors.forename: D M
authors.initials: DM
authors.lastname: Finkelstein
authors.forename: C
authors.initials: C
authors.lastname: Gatsonis
authors.forename: R D
authors.initials: RD
authors.lastname: Gelber
authors.forename: S
authors.initials: S
authors.lastname: Lagakos
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D004341:Drug Evaluation; D006801:Humans; D010043:Outcome and Process Assessment, Health Care; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
chemical_list: D010919:Placebos